London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
LO have not been selling for a while.They would be obliged to notify the market of any reduction of 1% of their holdings.That was upto yesterday in my opinion.They would wish to sell in a market that can absorb the volume they would want to offload.No one expected FUM to announce a USA deal so soon after FDA approval.This was massive news.It provided the environment in which to sell 1000000’s of shares.
In one sense this is a vote of confidence in FUM,however it surpresses the share price.LO should be issuing a RNS in the near future.They can be a bit tardy about timing!
Why has there not been a Procative interview? given this significant inflection point.Is FUM on holiday?
Can we expect another tranche after yesterdays news hense the MMs dropped price
Lombard is the conductor of the current share price, with the clout (around 100m shares) to determine its short term level. Great write up in The Sunday Times, followed by news of a US licensing deal with the giant Haleon makes daily trading volume yesterday balloon to over 8m shares, with over 1,000 trades, BUT the share price hardly budges. The significant level of involvement of Lombard is a two-edged sword: supportive at 8p, and through exercising warrants at 40p, but selling consistently above this level, so a stream of good news that would otherwise push the share price much higher has been nullified. Until Lombard stops selling, its share sales will create a brake on the share price, however good the news flow from Futura. A bit like Usain Bolt trying to set a world record into the wind: it can’t be done, or at least not easily, whereas if there is a big buyer or big buyers of the shares (the point of the recent investor open day) they would create a favourable following wind, and that horrid £1 discount to Libernum’s conservative current valuation would soon disappear.
Mis-valuations by the stock market do occur. Some companies respond by going private, others are taken over. Given the staggered release of Eroxon, we are years away from being able to see like-for-like sales globally, or even in the UK, where it’s still unavailable through eg the big supermarkets, and all the countless other places it’s possible to eg buy condoms. Until investors have a better idea of repeat sales for Eroxon, can create their spreadsheet models, sales trajectories, dividend forecasts, discount the cash flows etc, the counter armoury against the continued selling of Lombard is weak: reliance on newspaper tips, news coverage, news of new licensing deals. So far, this hasn’t been sufficient to offset Lombard’s selling.
In September, Futura really needs to present a transparent and compelling view of cash flows from sales, one that really excites potential investors, so that they consistently bid up the share price rather than simply waiting for the price to fall back on Lombard selling, one that replaces that horrid discount with a hefty premium, and one that gives all shareholders an exciting autumn 2023 and beyond to look forward to.
The BOD must have sales projections for god sake based on current great sales! Why are they not multiplying them up and releasing projections or at least something? Anything? Reason is beyond me!!!! Wish I’d never bought in as a LTH and just waited as it seems it’s a slow boat! IMO it will rocket on financial data SALES/REVENUE but until then who knows!
Taking into account the US$4mln in upfront payments Futura is set to receive, Liberum has upgraded its price target from 142p to 152p.
“We still see significant upside despite the strong recent performance and remain buyers,” said Liberum.
buy buy buy
From tiddler to world famous company in one RNS/
Lombard (an investment company) have millions of shares to off load and that is holding down the price imo.
FUM are now largely de-risked having signed a great partner in HALEON, taking the company into the largest ED market in the world and current sales are great. How is this stock still sitting in the low 50's?
Https://www.proactiveinvestors.co.uk/LON:FUM/Futura-Medical-PLC
Frustratingly, FUM is an AIM listed company. None of the economic rational applies here. The fund managers/pension accounts cannot invest in any company, unless it is FTSE 100 - 250 listed. Therefore, the road map for FUM is to increase its market cap to an extant to be included into FTSE market, so the city money starts to flow in. Which requires high-risk investors (such as LBO) to buy-in and pricipitate an increase in SP, hence market cap. I guess this will only happen when there is confidence in the perceived potential.
The sales figures and size of ED market is of little consequence to FUM. It all depends upon the revenue it receives ie the cut of the pie it receives, the deal it has cut for itself! All unknowns!
Haleon’s largest shareholder is Pfizer who holds 32% of Haleon. In other words, the big boss behind the deal today is Pfizer. So, just give them a year or two, you can expect Eroxon will follow the success path of Viagra.
If high volume of shares bought continues for several months, which signifies someone is accumulating the shares before a possible buy out. And that one will definite be Pfizer.
I am surprised this share price tracked downwards, clearly, not everyone is happy with the news.
Lucy Tobin aka The Tipster in Sunday Times headlined her piece this Sunday as 'Futura is looking for rapid growth'
She reminds readers that it has only 14 staff/directors working out of a small Surrey University Science park. She says that Futura has made a product that works and it is only just starting to shout about it. She makes clear things we might forget that Futura has minimised risk by outsourcing all it can; it does the science, but then, said James Barder, CEO "looks for commercial partners to do the rest." "We've done so in the UK, Europe and 7 countries in the Middle East. Saudi approval is expected in September - that's the biggest ED market in the Middle East." She was a day early for today's news re the US and probably thought like us it would fly.
It hasn't - but as sure as night follows day, unless male appendages start to shrink from too much Eroxon, then we are in for a sustained shareprice growth sooner or later. Initial sales at Boots were phenomenal - we know that - eventually these figures will become well known in the market and others will want their share of the action. Sit tight everyone our day is coming.
I must say I was disappointed with today's performance --
OK we don't know the details of any deal, but we could not hope for better partners
to take on the USA. I look forward to great progress !
Heck if HALEON like EROXON they might even want to look at FUMs diclofenac gel which looks at early stage better than HALEONs own diclofenac gel. https://www.futuramedical.com/what-we-do/pain-relief/tpr100-clinical-data/
Well let's see where this goes over next couple of weeks?
My bet past 70 and possibly upto a pound.
Broker said deal by ended 2023 would be great.
Reality deal done now!!! 5 to 6 months before even that hoped for date. $4 mill payment agreed plus together add ons.
Prior reports saidon sale in USA in 12 to 18 months .
RNS says onsale in USA SOON!!
Now soon to me is well well well before then.
The deal is done. Over!
Fantastic news and background info. Watch this develop momentum over there.
I am over the moon!
Look what happened with sales from initial Boots launch,plus ongoing 100 plus a day. Take No Notice of the Boots attempted review destruction. It obviously works % wise is my bet and has had numerous tests. Haleon wont have threw that money at it for the privilege without seeing latest confirmation of it all. Imagine when it is launched in the USA soon!!
This is primed and ready for lift off. And that is coming is my bet!
And steady worldwide deals to follow. Yes . Very pleased.
Read the RNS!
Yes the UK market is comical atm and I suspect that market makers are making little or no money these days hence the wild and illogical swings we see not only on AIM but on the larger cap indices too. It smacks of desperation just like some of the posters on here. UK Pension funds have exited UK listed companies over the past couple of years and focussed on overseas stocks and government securities and now that interest rates are higher than we have seen for many years, risk free returns of 5% are available ( T-bonds and gilts) so fund managers have taken the safe option to the detriment of listed companies. This won’t change a great deal until inflation is brought under control allowing interest rates to come down. When this eventually happens those same fund managers will have to work harder for their returns and do some research again into stock picking god forbid they are let loose again to do that! In the meantime if you have capital to allocate and time on your side investing in attractive growth prospects like Futura will IMO prove to be a good investment and this will become clearer when granular data is published. The lack of this data makes it too easy to knock potential future returns as we have seen today. You are either a believer that a good team of partners is being established to drive the growth of new sales across the globe with more to come and a very attractive free cash flow stream or you think that the Board will blindly give away everything that they have worked for a measly few % royalty deal. I think that I will back the management team to optimise returns now that we have reached this point in time after many tough years and I will happily wait for a year or two before the obvious potential is reflected in the financials.
Well lets
Sounds a little bit like 'The man who gave the Beatles away'
Taking into account the US$4mln in upfront payments Futura is set to receive, Liberum has upgraded its price target from 142p to 152p.
“We still see significant upside despite the strong recent performance and remain buyers,” said Liberum.
today's rsn content was poorly constructed (imo only). all that was required today was the name of the long awaited 'amazing' partner. the sp would have taken-off on just that news.
it is widely understood that company is not expected to release business sensitive information. however, releasing half-****ed, incomplete numbers, just went to further muddy the water.
i can see the us product and pricing to be totally different to eroxon. haleon plc will, independently have its own take on capturing the us market.
"futura will provide ongoing technical support...." only.
Unfortunately these days the market is controlled by the knuckle scrapers aided and abetted by the MMs. They cannot spell investing,never mind understand the meaning.
Hi, here is something I thought you might find interesting: - https://uk.investing.com/news/stock-market-news/haleon-an-excellent-choice-for-futuras-us-ambitions-says-broker-3085222
Again, shockin. No sooner do media outlets say " FUM surges and soars on US deal", that surge and soar has sunk. Dead cat bounce for today needed please lol.
All the AIM shares moves on the MM or some players whim. Almost impossible to do proper trading. They move by large amount without any news. Then mm's widens the spread to stop any one trading.